Back to Journals » Cancer Management and Research » Volume 9

Neoadjuvant chemotherapy followed by fast-track cytoreductive surgery plus short-course hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: preliminary results of a promising all-in-one approach

Authors Batista TP, Carneiro VCG, Tancredi R, Teles ALB, Badiglian-Filho L, Leão CS

Received 5 October 2017

Accepted for publication 12 November 2017

Published 13 December 2017 Volume 2017:9 Pages 869—878


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Antonella D'Anneo

Thales Paulo Batista,1,2 Vandré Cabral G Carneiro,1,3 Rodrigo Tancredi,4,5 Ana Ligia Bezerra Teles,6 Levon Badiglian-Filho,7 Cristiano Souza Leão8

1Department of Surgery/Oncology, IMIP – Instituto de Medicina Integral Professor Fernando Figueira, 2Department of Surgery, UFPE – Universidade Federal de Pernambuco, 3Department of Gynecology, HCP – Hospital de Câncer de Pernambuco, 4Department of Clinical Oncology, IMIP – Instituto de Medicina Integral Professor Fernando Figueira, 5Department of Clinical Oncology, HCP – Hospital de Câncer de Pernambuco, 6Department of Anaesthesiology, IMIP – Instituto de Medicina Integral Professor Fernando Figueira, Recife, 7Department of Gynecology, AC Camargo Cancer Center, Sao Paulo, 8Department of Surgery, IMIP – Instituto de Medicina Integral Professor Fernando Figueira, Recife, Brazil

Purpose: Hyperthermic intraperitoneal chemotherapy (HIPEC) has been considered a promising treatment option for advanced or recurrent ovarian cancer, but there is no clear evidence based on randomized controlled trials to advocate this approach as a standard therapy. In this study, we aim to present the early outcomes and insights after an interim analysis of a pioneering clinical trial in Brazil.
Methods: This study was a cross-sectional analysis of early data from our ongoing clinical trial – an open-label, double-center, single-arm trial on the safety and efficacy of using HIPEC for advanced ovarian cancer ( NCT02249013). A fast-track recovery strategy was also applied to improve patient outcomes.
Results: Nine patients with stage IIIB (n=1) or IIIC (n=8) epithelial malignancies were enrolled until February 2017. The median (range) serum CA125 level at diagnosis was 692 (223.7–6550) U/mL. The median number of preoperative cycles of intravenous (i.v.) chemotherapy was 3 (2–4), resulting in peritoneal cancer index scores of 9 (3–18) at the time of HIPEC. Time of restarting i.v. chemotherapy was 37 (33–50) days with all patients completing 6 cycles as planned. The median operation time was 395 (235–760) minutes, the length of hospital stay was 4 (3–10) days, and all the patients left the ICU on the morning after the procedure. Two patients experienced no postoperative complications, whereas 91% of the complications were minor G1/G2 events. Preliminary assessment also suggested no impairment of the patient’s quality of life.
Conclusion: Our comprehensive protocol might represent a promising all-in-one approach for advanced ovarian cancer. The patient recruitment for this trial is ongoing.

Keywords: hyperthermia, peritoneal neoplasms, peritoneal surface malignancy, peritoneal carcinomatosis, ovarian neoplasms

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License. The full terms of the License are available at The license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Download Article [PDF]  View Full Text [HTML][Machine readable]